Castelanich Desiree Giselle, Parra Hernandéz Luis A, Martinez Amado Andreina, Acevedo Diana A, Velásquez Lina, Dicker Valentina, Parra Hernandez Andrea M
Dermatology, Argentine Society of Dermatology, Buenos Aires, ARG.
Aesthetic Medicine, Sociedad Internacional de Rejuvenecimiento Facial No Quirúrgico (SIRF), Barranquilla, COL.
Cureus. 2024 Nov 23;16(11):e74297. doi: 10.7759/cureus.74297. eCollection 2024 Nov.
Although generally low-risk, hyaluronic acid (HA) dermal fillers can lead to late-onset edema, particularly in the periocular region. This condition typically manifests three to four months post-injection and requires specialized management, usually with hyaluronidase. However, increased use of hyaluronidase has resulted in instances of post-hyaluronidase syndrome, leading to unaesthetic outcomes. This study presents a retrospective case series that utilizes a novel technique combining two enzymes to improve late-onset edema and prevent post-hyaluronidase syndrome development.
From 2019 to 2024, six patients in our aesthetic clinic received a novel therapeutic approach involving co-administration of 1,500 IU of hyaluronidase and collagenase with a cannula to address late-onset edema in the periocular area.
The combination of high-dose hyaluronidase and low-dose collagenase improved late-onset edema in all patients after a single treatment. Statistical analysis showed a significant improvement in aesthetic scores (P < 0.05), with effect sizes of 0.89 for Hirmand, 1.3 for the Teoxane Infraorbital Hollows Scale (TIOHS), and 1.2 for O'Mahoney's photo-numeric scale. No post-hyaluronidase syndrome or complications were observed.
This combined technique utilizing 1,500 IU of hyaluronidase and collagenase GH PB220 from Pbserum (Madrid, Spain) effectively achieves significant aesthetic improvements with a high safety profile, offering a promising alternative for managing late-onset edema after HA dermal filler treatments.
尽管透明质酸(HA)真皮填充剂总体风险较低,但可能导致迟发性水肿,尤其是在眼周区域。这种情况通常在注射后三到四个月出现,需要特殊处理,通常使用透明质酸酶。然而,透明质酸酶使用的增加导致了透明质酸酶后综合征的病例,产生了不美观的结果。本研究呈现了一个回顾性病例系列,采用一种结合两种酶的新技术来改善迟发性水肿并预防透明质酸酶后综合征的发生。
2019年至2024年,我们美容诊所的六名患者接受了一种新的治疗方法,即通过套管联合注射1500国际单位的透明质酸酶和胶原酶,以解决眼周区域的迟发性水肿。
高剂量透明质酸酶和低剂量胶原酶联合使用在单次治疗后改善了所有患者的迟发性水肿。统计分析显示美学评分有显著改善(P < 0.05),希尔曼德评分的效应大小为0.89,特奥克斯眶下凹陷量表(TIOHS)为1.3,奥马奥尼照片数字量表为1.2。未观察到透明质酸酶后综合征或并发症。
这种使用1500国际单位透明质酸酶和来自西班牙马德里Pbserum公司的胶原酶GH PB220的联合技术,有效地实现了显著的美学改善,且安全性高,为HA真皮填充剂治疗后迟发性水肿的管理提供了一种有前景的替代方法。